Latest Ratios: P/E Ratio -4.0x · EV/EBITDA N/A · ROE -107.0%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $776M | $743M | $383M | $785M | $979M | $1.4B | $1.7B | $1.5B | $1.5B | $993M | $490M |
| Enterprise Value | $1.0B | $969M | $407M | $840M | $977M | $1.2B | $1.4B | $1.4B | $1.5B | $947M | $465M |
| P/E Ratio → | -3.99 | — | — | — | — | 11.24 | — | — | 15.37 | — | — |
| P/S Ratio | 4.56 | 4.36 | 4.59 | 8.70 | 8.68 | 3.05 | 10.94 | 42.66 | 7.04 | 95.59 | 106.75 |
| P/B Ratio | 7.54 | 7.23 | 1.47 | 2.52 | 1.90 | 1.88 | 4.48 | 3.34 | 3.02 | 5.43 | 3.03 |
| P/FCF | — | — | — | — | — | 10.66 | — | — | 16.83 | — | — |
| P/OCF | — | — | — | — | — | 6.56 | — | — | 14.69 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.68 | 4.89 | 9.31 | 8.66 | 2.50 | 9.22 | 41.01 | 6.72 | 91.10 | 101.34 |
| EV / EBITDA | — | — | — | — | — | 6.94 | — | — | 15.94 | — | — |
| EV / EBIT | — | — | — | — | — | 7.36 | — | — | 16.66 | — | — |
| EV / FCF | — | — | — | — | — | 8.74 | — | — | 16.06 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.1% | 88.1% | 59.7% | 58.8% | 51.6% | 89.0% | 76.9% | 76.6% | 95.6% | 83.6% | 79.1% |
| Operating Margin | -94.6% | -94.6% | -280.0% | -297.1% | -233.2% | 34.0% | -77.1% | -422.9% | 40.3% | -730.2% | -1423.8% |
| Net Profit Margin | -113.8% | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% | -72.0% | -268.9% | 45.7% | -704.0% | -1372.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -107.0% | -107.0% | -79.5% | -63.7% | -43.8% | 22.4% | -26.9% | -19.8% | 28.9% | -42.4% | -33.3% |
| ROA | -42.2% | -42.2% | -43.7% | -37.4% | -28.8% | 14.0% | -18.4% | -18.2% | 26.9% | -39.4% | -32.0% |
| ROIC | -39.4% | -39.4% | -53.8% | -45.7% | -38.7% | 38.8% | -35.5% | -26.9% | 23.0% | -41.7% | -32.7% |
| ROCE | -46.2% | -46.2% | -57.9% | -46.8% | -31.2% | 19.9% | -21.9% | -30.2% | 25.0% | -43.7% | -34.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.54 | 2.54 | 0.32 | 0.29 | 0.18 | 0.11 | 0.19 | 0.03 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.51 | — | — | 0.06 | — | — |
| Net Debt / Equity | — | 2.20 | 0.09 | 0.18 | -0.00 | -0.34 | -0.70 | -0.13 | -0.14 | -0.25 | -0.15 |
| Net Debt / EBITDA | — | — | — | — | — | -1.52 | — | — | -0.76 | — | — |
| Debt / FCF | — | — | — | — | — | -1.92 | — | — | -0.76 | — | — |
| Interest Coverage | -3.58 | -3.58 | -16.94 | -37.42 | -11.06 | 6.09 | -136.50 | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.38 | 2.38 | 2.69 | 2.57 | 3.19 | 3.98 | 6.52 | 10.25 | 15.24 | 11.64 | 9.66 |
| Quick Ratio | 2.38 | 2.38 | 2.69 | 2.57 | 3.19 | 3.98 | 6.39 | 10.25 | 14.98 | 11.27 | 9.47 |
| Cash Ratio | 1.95 | 1.95 | 2.27 | 2.11 | 2.80 | 3.51 | 5.84 | 8.80 | 14.42 | 11.14 | 9.26 |
| Asset Turnover | — | 0.38 | 0.18 | 0.16 | 0.14 | 0.42 | 0.22 | 0.07 | 0.40 | 0.05 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | 3.40 | — | 1.68 | 0.32 | 0.54 |
| Days Sales Outstanding | — | 56.49 | 94.47 | 106.54 | 98.09 | 25.17 | 101.54 | 395.20 | 14.34 | 16.61 | 82.08 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 8.9% | — | — | 6.5% | — | — |
| FCF Yield | — | — | — | — | — | 9.4% | — | — | 5.9% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $52M | $50M | $44M | $43M | $44M | $37M | $37M | $37M | $30M | $26M |
Imminent liquidity and dilution
According to recent market data, RGNX trades at a price-to-sales multiple of 3.18, which appears to discount the company's long-term platform potential in favor of immediate concerns regarding its clinical-stage status and the high volatility inherent in its milestone-dependent revenue recognition model compared to commercial-stage peers.
The current P/S multiple suggests that investors are pricing the stock as a speculative platform play rather than a stable revenue-generating entity. Given the lack of consistent earnings, traditional P/E metrics are non-informative, and the valuation appears highly sensitive to the success of the RGX-314 pipeline rather than current licensing cash flows.
As reported in financial statements, RGNX's ROIC has deteriorated to -30.8% in 2026Q1, illustrating a persistent inability to generate positive returns on invested capital as the company continues to prioritize heavy R&D spending over immediate profitability in its pursuit of long-term gene therapy commercialization.
The negative ROIC trend highlights the significant capital intensity required to maintain the NAV platform and internal manufacturing facilities. This decay in capital efficiency suggests that the company is currently in a value-destructive phase, where the cost of developing its pipeline significantly outweighs the returns generated from its licensing activities.
Based on reported figures, the company's asset turnover ratio has remained stagnant at 0.02 in 2026Q1, reflecting a structural inefficiency in converting its substantial investment in manufacturing infrastructure into meaningful revenue streams compared to the more agile, asset-light models seen in some platform-focused biotechnology competitors.
The erratic nature of the company's DSO and DPO metrics suggests that management faces significant challenges in managing cash conversion cycles, likely due to the lumpy and unpredictable timing of milestone payments. This inefficiency underscores the operational difficulty of balancing high fixed-cost infrastructure with a revenue model that lacks recurring, predictable cash inflows.
According to recent SEC filings, RGNX's debt-to-equity ratio has climbed to 3.37, a concerning shift that indicates an increasing reliance on debt to fund operations as the company's equity base continues to erode under the pressure of sustained, high-intensity clinical development and operational cash burn.
The rising leverage profile warrants close monitoring, as the company's ability to service debt appears increasingly constrained by its negative operating margins. Investors should consider this trend a signal of potential financial distress, as the firm lacks the consistent cash flow generation required to support such a debt-heavy capital structure.
Based on an analysis of the company's business model, the P/S ratio is the most commonly misapplied metric, as it fails to account for the non-recurring nature of milestone payments that artificially inflate revenue in specific quarters without reflecting the underlying commercial health of the business.
Using P/S to value RGNX obscures the reality that the company is not yet a commercial-stage entity with recurring product sales. Analysts should instead focus on cash runway and the probability-weighted net present value of the clinical pipeline, as these metrics provide a more accurate assessment of the company's long-term viability than headline revenue multiples.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RGNX stock.
REGENXBIO Inc.'s current P/E ratio is -4.0x. The historical average is 13.3x.
REGENXBIO Inc.'s return on equity (ROE) is -107.0%. The historical average is -35.1%.
Based on historical data, REGENXBIO Inc. is trading at a P/E of -4.0x. Compare with industry peers and growth rates for a complete picture.
REGENXBIO Inc. has 88.1% gross margin and -94.6% operating margin.